To further service this growing market, the company recently opened a new GMP1 standard facility in South Korea, althought he company has had a presence in the country since 1994.
Specifically, Thermo Fisher’s Clinical Services business has been servicing the clinical research market in Korea through its Asia Pacific Hub – Clinical Services Singapore.
“Although this support has been working well, we identified Korea as a country of high growth for clinical research as many large pharmaceutical and biotech companies are planning to conduct clinical trials there,” Leon Wyszkowski, VP of clinical services for North America, Thermo Fisher Scientific, told Outsourcing-Pharma.com.
“Having a direct presence in the region for Clinical Services is paramount for not only those companies, but also for Korean pharmaceutical companies who are seeking help from Clinical Services when conducting global trials, outside of Korea,” he added.
Wyszkowski explained that the expansion allows the company to provide a “one-stop service” for clinical supplies, including cGMP storage, local labelling, secondary packaging, coordination of comparator procurement, handling and distribution of ambient and cold chain supplies, and clinical site returns management.
“Additionally, having local project management expertise with an understanding of the import/export and regulatory requirements will support pharmaceutical companies in getting supplies to patients at the right time and the right place,” he said.